Sharemaestro Newsreel

Innovative Eyewear Reports 74% Revenue Growth in Q2

Innovative Eyewear reported a significant 74% year-over-year revenue growth in Q2 2026, reaching over $1 million for the first time. The company also improved its gross margin to 24% and reduced operating expenses, demonstrating effective cost management. With strategic initiatives and partnerships, Innovative Eyewear …

Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Is iRhythm Holdings (IRTC) Undervalued Following Earnings And Higher 2026 Guidance?

What Pfizer (PFE)'s EMA Lyme Vaccine Filing and Updated Outlook Means For Shareholders

Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake

Squadron Master Fund LP and related entities, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have reported a beneficial ownership stake of 810,000 shares in Lipocine Inc. (LPCN). This represents 9.8% of the company's outstanding shares as of May 6, 2026. The …

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics

The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection) for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology. Lantheus plans to support Alzheimer's therapeutic programs and is evaluating commercial …

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals. The combined company is advancing a portfolio of clinical-stage therapies …

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?

Kodiak Sciences (NASDAQ:KOD) shares gapped down before Friday's market open, though they later recovered some ground. The clinical-stage biopharmaceutical company, which focuses on retinal disease treatments, reported a quarterly loss that missed analyst estimates. Despite the earnings miss, analyst sentiment is generally positive, with …

Beyond Air Inc (XAIR) Stock News Today

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8

Citi has reiterated its Buy rating for Caribou Biosciences (CRBU.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.

PTCT Maintained by Barclays -- Price Target Raised to $122

Barclays has maintained an "Overweight" rating for PTC Therapeutics (PTCT) and increased its price target to $122.00 from $120.00. Despite this positive analyst outlook, GuruFocus indicates the stock is significantly overvalued at $71.52 against a GF Value of $37.55, with a mixed GF Score …

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has reported a beneficial ownership of 9.96% in CytomX Therapeutics (CTMX). This group collectively holds shared voting and dispositive power over 21,703,093 shares of common stock. The disclosure was made …

Innovative Eyewear Q2 EPS $(0.26) beats estimate, sales rise 74%

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a …

Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares

Highbridge Capital Management, LLC has disclosed a beneficial ownership of 6.1% in Annovis Bio, Inc., which is tied to 2,775,578 shares of common stock issuable upon the exercise of warrants. This stake is calculated based on 42,541,868 outstanding common shares after a referenced offering …

Llamada de resultados del T2 de 2026 de Dyadic International (DYAI): progreso comercial y riesgo de liquidez

Dyadic International (DYAI) reportó ingresos estables en el segundo trimestre de 2026 de $961,000, con una pérdida neta que aumentó a $2.1 millones, y sus ingresos del primer semestre crecieron un 52% a $2.1 millones. A pesar de los progresos comerciales, la empresa finalizó …

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movement, making CDXS an attractive investment. The …

Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has raised its price target for Upstream Bio (NASDAQ:UPB) to $9.00 from $8.00, maintaining a "neutral" rating. This new target suggests a potential upside of 29.22% from the stock's current price of $6.96. The company recently reported a quarterly loss …

Sensus Healthcare, Inc. Q2 2026: Revenue $2.29M, EPS $(0.53) — 10-Q Summary

Sensus Healthcare, Inc. (SRTS) reported a significant decline in its Q2 2026 financial results, with revenue falling to $2.29M and diluted EPS at $(0.53). This downturn was primarily attributed to fewer system sales, a shift towards Fair Deal Agreements and rental arrangements impacting revenue …

Butterfly Network (NYSE:BFLY) Shares Down 4.4% - Here's What Happened

Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7% - Here's Why

HTFL Maintained by Wells Fargo -- Price Target Raised to $39

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00

Wells Fargo has maintained an Equal-Weight rating for Cabaletta Bio Inc (CABA) but lowered its price target from $4.00 to $3.00, reflecting a cautious outlook. The company's GF Score™ of 34/100 indicates significant weaknesses in profitability and growth, despite strengths in financial stability and …

AVAH Q2 Earnings Call Highlights Higher Growth Targets